• Holds 515,544 BNB tokens with a fair value of approximately $302.3 million at July 31, 2026
  • Repurchased 1,434,112 shares of common stock for $3.8 million at an average price of $2.63 per share
  • Reports first quarter fiscal 2027 net loss of $11.4 million, or $(0.22) per diluted share

LOUISVILLE, CO, Sept. 11, 2026 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq: BNC) (“CEA Industries,” “BNC,” or the “Company”), a growth-oriented company focused on managing the world’s largest corporate treasury of BNB, today announced its financial results for the first quarter of fiscal 2027, ended July 31, 2026.

First Quarter Fiscal 2027 Financial Highlights

  • Net Loss: Reported a net loss of $11.4 million, or $(0.22) per basic and diluted share. Results were driven primarily by a $15.3 million unrealized loss on digital assets, of which $15.0 million related to BNB, partially offset by a $10.0 million non-cash gain on the change in fair value of warrant liabilities.
  • Digital Asset Holdings: At July 31, 2026, the Company held 515,544 BNB tokens (471,346 unrestricted and 44,198 pledged as loan collateral) with a fair value of $302.3 million, unchanged in token count from April 30, 2026. Including BTC and USDT positions, total digital assets had a fair value of $304.5 million and represented 93.1% of total assets.
  • Treasury Yield: Generated $0.3 million of Airdrop income within the Binance ecosystem, reflecting a continued moderation in Airdrop, Launchpool and HODLer program activity across the ecosystem.
  • Revenue and Gross Profit: Revenue from the Retail and Industry segment was $7.2 million, compared to $7.5 million in the combined prior-year quarter, a decrease of 4.6% driven primarily by the discontinuance of a product line at Fat Panda. Gross profit was $2.0 million, compared to $2.3 million in the combined prior-year period corresponding to the revenue decline.
  • Operating Expenses: Total operating expenses were $23.2 million, including the $15.3 million unrealized loss on digital assets described above, $1.4 million of shareholder advisory expenses related to the activism campaign resolved in June 2026 and $1.1 million of management fees under the Asset Management Agreement. The Company does not expect to incur material additional shareholder advisory costs related to the resolved activism campaign.
  • Liquidity: Ended the quarter with $7.1 million of cash and cash equivalents, up from $3.1 million at April 30, 2026. The Company drew $15.0 million of USDC under its master loan facility, secured by 44,198 BNB valued at $25.9 million at quarter end, without liquidating core treasury assets. Total debt outstanding was $16.8 million. The Company was in compliance with all debt covenants at July 31, 2026.
  • Share Repurchases: During the quarter, the Company repurchased and cancelled 1,434,112 shares of common stock at an average price of $2.63 per share for a total of $3.8 million under its $250 million share repurchase program authorized in September 2025.
  • Balance Sheet: Total assets were $327.2 million and total shareholders’ equity was $289.4 million at July 31, 2026. Shares of common stock outstanding were 41,173,850, down from 42,607,962 at April 30, 2026 resulting from the aforementioned share repurchases.

Corporate Governance and Operational Highlights

  • Cooperation Agreement with YZILabs: On June 23, 2026, the Company entered into a cooperation agreement with YZILabs resolving the consent solicitation and related activism campaign commenced in November 2025. YZILabs terminated its consent solicitation and withdrew its related demands and is subject to standstill, voting and mutual non-disparagement covenants. The Board was increased to six directors with the appointments of Ling “Ella” Zhang, Alex Odagiu and Matthew Roszak, and the parties agreed to appoint a seventh mutually agreeable director, which remains pending.
  • Board and Leadership Evolution: Carly E. Howard was named Chair of the Board effective May 6, 2026. Alex Odagiu has served as Interim President, reporting directly to the Board, since June 23, 2026. On July 22, 2026, David Namdar concluded his service as Chief Executive Officer in accordance with his March 2026 transition agreement, and the Board appointed William B. Miller, Chief Financial Officer, to serve additionally as Interim Principal Executive Officer without additional compensation. The Board formed a chief executive officer search committee on June 29, 2026 and its search is ongoing.
  • Nasdaq Listing Compliance: On August 5, 2026, Nasdaq notified the Company that it had regained compliance with Listing Rule 5620(a) following the July 22, 2026 special meeting and that the matter is closed.
  • Asset Management Agreement (AMA) Litigation: The Company filed a complaint on May 22, 2026 in the U.S. District Court for the District of Delaware, seeking to void the AMA from inception and, in the alternative, a declaration that the agreement’s liquidated damages provision is an unenforceable penalty, remains pending. The Asset Manager moved to dismiss on July 28, 2026 and the Company filed its opposition on August 14, 2026. The Company has not terminated the AMA and no amount is presently due under that provision.
  • Retail Operations: At July 31, 2026, Fat Panda operated 34 retail locations across Central Canada, comprised of 30 Fat Panda branded stores and 4 Electric Fog branded outlets, together with an e-commerce platform and in-house premium e-liquid manufacturing.

Business Outlook

CEA Industries remains committed to the disciplined execution of its BNB digital asset treasury strategy. With the shareholder activism campaign resolved, the Board substantially reconstituted and Nasdaq annual meeting deficiency restored, the Company’s near-term priorities are focused on driving operational and strategic execution and resolving the pending Asset Management Agreement litigation.

The Company intends to continue holding its position as the world’s largest corporate BNB treasury and, when capital allows, may add to its BNB holdings. CEA Industries also plans to continue to evaluate additional treasury management opportunities within the BNB ecosystem, while maintaining a disciplined approach to liquidity, risk management and shareholder value creation.

About CEA Industries Inc.

CEA Industries Inc. (Nasdaq: BNC) is a growth-oriented company that focuses on building category-leading businesses in consumer markets, including building and managing the world’s largest corporate treasury of BNB.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws, which reflect our current views with respect to, among other things, our operations and financial performance. You can identify these forward-looking statements by the use of words such as “outlook,” “believe,” “expect,” “potential,” “continue,” “may,” “should,” “seek,” “approximately,” “predict,” “intend,” “will,” “plan,” “project,” “target,” “estimate,” “anticipate,” “conviction,” the negative version of these words, other comparable words or other statements that do not relate strictly to historical or factual matters. By their nature, forward-looking statements speak only as of the date they are made, are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. BNC’s expectations, beliefs and projections are expressed in good faith and BNC believes there is a reasonable basis for them. However, there can be no assurance that BNC’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the Company’s execution of its BNB digital asset treasury strategy, driving operational and strategic execution and resolving the pending Asset Management Agreement litigation, the Company’s position as the world’s largest corporate BNB treasury, the Company’s BNB holdings, treasury management opportunities within the BNB ecosystem, the Company’s expectations with respect to shareholder advisory costs, the Company’s director search, the Company’s CEO search, the Company’s financial condition and liquidity outlook, the Company’s future financial results, share repurchases, strategy, plans, objectives, expectations (financial or otherwise) and growth potential, and the Company’s ability to create shareholder value. BNC wishes to caution readers that these forward-looking statements may be affected by the risks and uncertainties in BNC’s business, as well as other important factors that may have affected and could in the future affect BNC’s actual results and could cause BNC’s actual results for subsequent periods to differ materially from those expressed in any forward-looking statement made by or on behalf of BNC. In evaluating these forward-looking statements, readers should consider various risk factors, which include, but are not limited to: volatility in the market price of BNB and other digital assets; the concentration of BNC’s holdings in BNB and of its custody arrangements within the Binance ecosystem; collateral maintenance and repayment obligations under BNC’s master loan facility; the outcome of the AMA litigation, BNC’s non-payment of accrued management fees, and the enforceability of the AMA’s liquidated damages provision; BNC’s ability to appoint a permanent chief executive officer and an additional independent director within the deadlines under the Cooperation Agreement; the previously disclosed material weakness in BNC’s internal control over financial reporting; BNC’s continued compliance with Nasdaq listing requirements; BNC’s ability to finance its current business and proposed future business, including the ability to finance the continued acquisition of BNB; evolving laws, regulations and accounting guidance applicable to digital assets; the future value and adoption of BNB; shareholder activism; outcome of the Company’s director and CEO searches; and execution of the Company’s BNB digital asset treasury strategy.

Forward-looking statements are subject to numerous conditions and risks, many of which are beyond BNC’s control. In addition, these forward-looking statements and the information in this press release are qualified in their entirety by cautionary statements and risk factor disclosures contained in BNC’s filings with the SEC, including BNC’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and BNC’s subsequent filings with the SEC, as each may be amended or supplemented from time to time. Copies of BNC’s filings with the SEC are available on the SEC’s website at www.sec.gov. BNC undertakes no obligation to update these forward-looking statements for revisions or changes after the date of this press release, except as required by law.

CEA Industries Media Inquiries:
bnc@cw8.co

CEA Industries Investor Relations:
james@haydenir.com

INDIANAPOLIS, Sept. 11, 2026 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG) announced today that it will present at the BofA Securities 2026 Global Real Estate Conference. The presentation information is as follows:

Event: Kite Realty Group Management Presentation
When: September 15, 2026, at 3:00 p.m. ET
Live Webcast: Kite Realty Group BofA Securities 2026 Global Real Estate Conference
Investor Presentation: KRG Q2 2026 Investor Update

A replay of the webcast will be available at kiterealty.com following the completion of the conference.

About Kite Realty Group

Kite Realty Group (NYSE: KRG) is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of open-air shopping centers and mixed-use destinations. The Company’s portfolio is concentrated in high-growth Sun Belt and select strategic gateway markets. Publicly listed since 2004, KRG brings more than six decades of experience in developing, operating, and investing in real estate, using a disciplined, hands-on approach to enhance portfolio quality and maximize long-term value for all stakeholders. As of June 30, 2026, the Company owned interests in 165 U.S. open-air shopping centers and mixed-use assets, comprising approximately 26.4 million square feet of gross leasable space. For more information, please visit kiterealty.com.

Connect with KRG: LinkedIn | X | Instagram | Facebook

Contact Information: Kite Realty Group
Cooper Clark
VP, Capital Markets & Investor Relations
773.980.0213
coclark@kiterealty.com

SAN MATEO, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Oportun Financial Corporation (“Oportun”, or the “Company”) today announced that, on September 10, 2026, in accordance with the offer letter agreement with Sean Rowles, the Company’s Chief Risk Officer, previously announced by the Company on June 16, 2026, it granted a long-term new hire equity award consisting of 382,653 restricted stock units representing the right to receive an equivalent number of shares of the Company’s common stock (“RSUs”) and 127,551 performance-vesting restricted stock units representing the right to receive an equivalent number of shares of the Company’s common stock at target (“PSUs”) to Mr. Rowles, effective on September 10, 2026. The RSUs and PSUs were an inducement material to Mr. Rowles entering into employment with the Company and granted under and subject to the terms of the Company’s Amended and Restated 2021 Inducement Equity Incentive Plan and applicable award agreements. The RSUs will vest as to one-third of the award on the one-year anniversary of the grant date and as to the remaining two-thirds of the award in eight substantially equal quarterly installments, such that the RSUs will be fully vested on the third anniversary of the grant date. The PSUs are eligible to vest after the end of the three-year performance period, based on a combination of performance goals and vesting terms. The vesting of the RSUs and PSUs is generally subject to Mr. Rowles remaining in continuous service with the Company through the relevant vesting dates. Mr. Rowles’s offer letter agreement was filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 18, 2026. The Amended and Restated 2021 Inducement Equity Incentive Plan and the forms of RSU and PSU award agreements are filed as exhibits to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026.

About Oportun

Oportun (Nasdaq: OPRT) is a mission-driven financial services company that puts its members’ financial goals within reach. With intelligent borrowing, savings, and budgeting capabilities, Oportun empowers members with the confidence to build a better financial future. Since inception, Oportun has provided more than $22.7 billion in responsible and affordable credit, saved its members more than $2.5 billion in interest and fees, and helped its members set aside an average of more than $1,800 annually.

For more information, visit Oportun.com.

Investor Contact
Dorian Hare
(650) 590-4323
ir@oportun.com

Media Contact
Michael Azzano
Cosmo PR for Oportun
(415) 596-1978
michael@cosmo-pr.com

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company’s Special and Extraordinary General Shareholders’ Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Company’s Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants.

“We are grateful for the support of our shareholders and excited to formally welcome Marino and Naimish to our Board,” said Tim Knotnerus, Chief Executive Officer of Agomab. “Both bring exceptional and complementary experience that will be highly valuable as we continue to advance our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases. We look forward to benefiting from their perspectives as we work to create meaningful value for patients and shareholders alike.”

Marino Garcia commented, “I am honored to join Agomab’s Board at such an exciting stage in the Company’s development. Agomab has built a compelling pipeline targeting fibro-inflammatory diseases with significant unmet need, supported by a talented leadership team and strong scientific foundation. I look forward to working closely with the Board and management team to help advance the Company’s strategy and long-term vision.”

Naimish Patel, M.D., added, “I am delighted to join Agomab’s Board and contribute to the Company’s mission of developing innovative therapies for patients with fibro-inflammatory diseases. The combination of strong science, clear clinical focus and commitment to addressing significant unmet medical needs creates an exciting opportunity. I look forward to bringing my experience in translational medicine and clinical development to support Agomab’s continued progress.”

The Company also announced that shareholders approved the proposed consolidation and split adjustment of outstanding pre-IPO warrants, aligning such warrants with the share split implemented in connection with Agomab’s IPO in February 2026.

The materials relating to the Special and Extraordinary General Shareholders’ Meeting, including the biographies of the newly appointed Board members, are available on the Company’s website.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, express and implied statements regarding the anticipated contributions of Marino Garcia and Naimish Patel, M.D. to the Company’s Board of Directors, the Company’s strategy and long-term vision, and the continued advancement of our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to advance our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu 
Phone: +49 172 861 8540

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn. 

CONTACT: Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (the “Company”) today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock“). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business-combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.

The merger of Impact BioMedical Inc. and Zoar Ltd, upon approval, will result in a new company with manufacturing and clinical development expertise across a broad spectrum of active pharmaceutical ingredients (API’s) and intermediates for life-saving drugs worldwide, with immediate focus on emerging markets. It will also include significant intellectual property with potential in human health and wellness markets.

( Read the original merger announcement here.).  

Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Ltd. for every four (4) shares of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.

The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.

Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact BioMedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.

Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:

  • Outstanding equity awards and related exercise prices
  • Shares available under equity incentive plans
  • Other relevant share-based agreements

The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.

Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC“) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.

About Zoar Ltd.
Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:
Impact BioMedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com

CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 5,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $12.93 per share, the closing price per share of Korro’s common stock as reported by Nasdaq on the grant effective date, September 9, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee’s applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee’s applicable start date, subject to the employee’s continued service with Korro through each applicable vesting date.

These grants were approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and were made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information

Investor & Media Contact 
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker in the event. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic option for obesity beyond GLP-1 and other incretin-targeting therapies.

The CANYON-1 Phase 1b clinical trial is a 16-week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adult participants conducted at multiple clinical sites in the United States (NCT07310901). The trial includes three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily (QD) as well as a placebo cohort (randomization of 1:1:1:1). A dose titration regimen was included in the design, with all participants receiving CRB-913 commencing at 20 mg/day and then titrating up to either 40 mg/day or beyond that to 60 mg/day, depending on their assigned cohorts. Participants were dosed for 12 weeks followed by a four-week safety follow-up.

Registration Details
 
Date: Monday, September 14, 2026
   
Time: 8:00 a.m. EDT
   
Registration: Click here
   
A replay will be available on the Corbus website following the event.
 

About Harold Bays, M.D.

Dr. Harold Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Obesity Medicine and Diplomate of the American Board of Clinical Lipidology. He is Medical Director Louisville Metabolic and Atherosclerosis Research Center/ Monroe Biomedical Research and Clinical Associate Professor at the University of Louisville School of Medicine. He has served as an Investigator for over 700 Phase I – IV clinical trials regarding treatments for obesity, dyslipidemias, diabetes mellitus, hypertension, and other cardiometabolic and hormonal disorders. Dr. Bays is Chief Science Officer of the Obesity Medicine Association and is Editor in Chief for Obesity Pillars – the journal of the Obesity Medicine Association. Dr. Bays was President of the Obesity Medicine Association in 2025 – 2026. Dr. Bays has written and/or served as a contributing author for approximately 400 peer review scientific manuscripts and book chapters, hundreds of scientific abstracts presented at major scientific meetings. He has served as first author and/or co-author for scientific consensus statements, position statements, and clinical practice statements in Obesity Medicine and Clinical Lipidology. He is a Fellow of the Obesity Medicine Association (FOMA), Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), Fellow of the American College of Cardiology (FACC), and Fellow of the American Society of Preventive Cardiology (FASPC). Dr. Bays originated the term “adiposopathy” (“sick fat”), which defines how and when the pathogenic consequences of adipose tissue accumulation promote metabolic disease, including dyslipidemia, diabetes mellitus, and hypertension. Dr. Bays has received several scientific awards in such as the 2016 Obesity Medicine Association “Obesity Medicine Association Clinician of the Year,” 2026 Obesity Medicine Association Research Award, and 2015 National Lipid Association “President’s Service Award.” Finally, in 2026, Clarivate designated Dr. Bays as a “Highly Cited Researcher,” defined as having authored “multiple Highly Cited Papers that rank in the top 1% by citations for their field(s) and publication year in the Web of Science Core Collection – indicating exceptional influence in their respective disciplines.”

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

SPRINGFIELD, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Village Super Market, Inc. (NSD:VLGEA) declared quarterly cash dividends of $0.25 per Class A common share and $0.1625 per Class B common share. The dividends will be payable on October 22, 2026 to shareholders of record at the close of business on October 1, 2026.

Village Super Market operates a chain of 34 supermarkets in New Jersey, New York, Maryland and Pennsylvania under the ShopRite and Fairway banners and three Gourmet Garage specialty markets in New York City.

Contact: John Van Orden, CFO
  (973) 467-2200
  VillageInvestorRelations@wakefern.com

CALGARY, Alberta, Sept. 11, 2026 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE: GTE) today announced that it is conducting a solicitation (the “Consent Solicitation”) of consents (the “Consents”) from Holders of its 9.750% Senior Secured Amortizing Notes due 2031 (the “Notes”) to effect certain proposed amendments (the “Proposed Amendments”) to the indenture dated as of February 18, 2026, under which the Notes were issued (the “Indenture”), pursuant to the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated September 11, 2026 (the “Consent Solicitation Statement”). Any capitalized terms used in this press release without definition have the respective meanings assigned to such terms in the Consent Solicitation Statement.

Notes CUSIP/ISIN Numbers Principal Amount
Outstanding
Consent Fee
9.750% Senior Secured
Amortizing Notes due
2031
Rule 144A: 38500T AD3 / US38500TAD37
Regulation S: U37016 AF6 / USU37016AF67
US$479,353,000 US$2.50 per US$1,000

As previously announced, on August 5, 2026, the Company entered into a Share Sale and Purchase Agreement (as it may be amended from time to time in accordance with its terms, the “Share Purchase Agreement”) with Établissements Maurel et Prom S.A., a company organized and existing under the laws of France (“M&P”), Maurel & Prom Andina S.A.S., a company organized and existing under the laws of France and an indirect wholly owned subsidiary of M&P (“Purchaser”), and the other parties thereto, whereby, among other things, Gran Tierra Energy International Holdings GmbH, a company organized and existing under the laws of Switzerland and an indirect wholly owned subsidiary of the Company, has agreed to sell all of the issued and outstanding equity interests of Gran Tierra Energy CI GmbH, a company organized and existing under the laws of Switzerland and an indirect wholly owned subsidiary of the Company (“GTECI”), to Purchaser (the transactions contemplated by the Share Purchase Agreement, the “Sale”). At Completion (as defined in the Share Purchase Agreement), among other things, Purchaser will assume the performance of every covenant and all obligations of the Company under the Indenture, the Notes, and the applicable collateral documents (to the extent not released) (the “Note Assumption”).

The Proposed Amendments would (i) enable the Note Assumption by releasing certain collateral, waiving debt coverage tests related to successor issuers for purposes of the Sale and providing that the Sale is not a Change of Control under the Indenture, (ii) update the definition of “GAAP” in the Indenture to include International Financial Reporting Standards as issued and interpreted by the International Accounting Standards Board and accounting principles that are recognized as being generally accepted in France, (iii) update the financial reporting covenant, including to reflect that neither M&P nor Purchaser is an SEC-reporting company and to permit the reporting of hydrocarbon proved reserve information pursuant to the Petroleum Resources Management System of the Society of Petroleum Engineers, and (iv) provide that certain acquisitions of working interests in the Sinu-9 gas license in Colombia by Purchaser or any Restricted Subsidiary (as defined in the Indenture) from certain affiliates of M&P will be considered a “Permitted Investment” under the Indenture. No other changes will be made to the Indenture or the Notes. The interest rate, payment terms, and maturity date of the Notes will remain the same, and the Notes will remain secured by a first-ranking pledge by GTECI in respect of all of the quotas and other equity securities of any kind of Gran Tierra Energy Colombia GmbH and Gran Tierra Operations Colombia GmbH.

The Proposed Amendments must be consented to by Holders of not less than 50% in aggregate principal amount of the Notes outstanding (the “Requisite Consents”) in order to be effective.

Subject to the terms and conditions of this Consent Solicitation Statement, the Company is offering Holders of Notes who validly deliver (and do not validly revoke) their consents prior to the Expiration Time (as defined below) (each such Holder a “Consenting Holder”) consent consideration equal to US$2.50 per US$1,000 in principal amount of Notes held by such Consenting Holder (the “Consent Fee”) payable on the closing date of the Sale.

Consummation of the Consent Solicitation and payment of the Consent Fee are conditioned upon the satisfaction or waiver of the conditions described in the Consent Solicitation Statement, including, among other things, obtaining the Requisite Consents and the completion of the Sale. If the Requisite Consents have not been obtained by the Expiration Time (as defined below), the Company may, in its discretion and without limitation, extend the Consent Solicitation in order to seek to obtain the Requisite Consents or cause the other conditions to the Consent Solicitation to be satisfied.

Holders of the Notes must validly deliver their Consents at or prior to 5:00 p.m., New York City time, on September 22, 2026, unless extended or earlier terminated by the Company, in its sole discretion (such date and time, as the same may be extended or earlier terminated, the “Expiration Time”). A Holder may validly revoke its Consent prior to the earlier of the Expiration Time and the time of execution of the Supplemental Indenture (such date and time, as the same may be extended, the “Withdrawal Deadline”). Holders who deliver their Consents at or prior to the Expiration Time (and do not validly revoke such Consents at or before the Withdrawal Deadline) will be eligible to receive the Consent Fee.

If the Requisite Consents are received, it is expected that a Supplemental Indenture setting forth the Proposed Amendments will be entered into by the Company, the Note Guarantors and the Trustee promptly after receipt of such Requisite Consents, whether before or after the Expiration Time. The Supplemental Indenture will give effect to the Proposed Amendments and will be effective upon execution, but will only become operative on the closing date of the Sale.

The Company reserves the right to modify the Consent Solicitation Statement and the terms and conditions of the Consent Solicitation or to terminate the Consent Solicitation.

BofA Securities, Inc. is serving as sole Solicitation Agent in the Consent Solicitation and D.F. King & Co. Inc. has been retained to serve as the Information and Tabulation Agent. Persons with questions regarding the Consent Solicitation should contact BofA Securities, Inc. at (toll free) (888) 292-0070 or (collect) (646) 855-8988. Requests for the Consent Solicitation Statement should be directed to D.F. King & Co. Inc., at (toll free) (888) 548-6498, (banks and brokers) (646) 582-9168 or by email to gte@dfking.com.

None of the Company, the Solicitation Agent, the Trustee under the Indenture, or the Information and Tabulation Agent makes any recommendation as to whether or not Holders should deliver Consents in the Consent Solicitation.

This press release is not a solicitation of consents with respect to the Proposed Amendments or otherwise. The Consent Solicitation is being made solely through the Consent Solicitation Statement referred to above and related materials. The Consent Solicitation is not being made to Holders of Notes in any jurisdiction where the making of the Consent Solicitation would not be in compliance with the laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Consent Solicitation to be made by a licensed broker or dealer, the Consent Solicitation will be deemed to be made on the Company’s behalf by the Solicitation Agent or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction. Neither the Consent Solicitation Statement nor any documents related to the Consent Solicitation have been filed with, or approved or reviewed by, any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Consent Solicitation Statement or any documents related to the Consent Solicitation, and it is unlawful and may be a criminal offense to make any representation to the contrary.

Contact Information

For investor and media inquiries please contact:
Gary Guidry, Chief Executive Officer
Ryan Ellson, Executive Vice President & Chief Financial Officer
+1-403-265-3221
info@grantierra.com

About Gran Tierra Energy Inc.

Gran Tierra Energy Inc., together with its subsidiaries, is an independent international energy company currently focused on oil and natural gas exploration and production in Canada, Colombia, Ecuador and Azerbaijan. Upon completion of the Sale described in this press release, the Company’s producing operations will be focused on Canada, and the Company will continue to pursue its exploration interests in Azerbaijan and additional new growth opportunities that would further strengthen the Company’s portfolio. The Company’s common stock trades on the NYSE American, the Toronto Stock Exchange and the London Stock Exchange under the ticker symbol GTE. Additional information concerning Gran Tierra is available at www.grantierra.com. Except to the extent expressly stated otherwise, information on the Company’s website or accessible from our website or any other website is not incorporated by reference into and should not be considered part of this press release. Investor inquiries may be directed to info@grantierra.com or (403) 265-3221.

Gran Tierra’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available on the SEC website at http://www.sec.gov. Gran Tierra’s Canadian securities regulatory filings are available on SEDAR+ at http://www.sedarplus.ca and UK regulatory filings are available on the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Forward Looking Statements and Legal Advisories:

This press release contains opinions, forecasts, projections, and other statements about future events or results that constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and financial outlook and forward looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”), which can be identified by such terms as “expect,” “plan,” “can,” “will,” “should,” “guidance,” “estimate,” “forecast,” “intend,” “anticipate,” “believes,” and “remains subject to,” derivations thereof and similar terms are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, the form and results of the Consent Solicitation; the Company’s ability to obtain amendments to the Indenture; statements regarding the anticipated benefits of the Sale; the satisfaction of the conditions precedent to, and the timing of the completion of, the Sale; the receipt of the Requisite Consents of the Holders; the expected closing date of the Sale; the Note Assumption and the related reduction of the Company’s net debt; the Company’s strategy and growth plans in Canada and Azerbaijan.

The forward-looking statements contained in this press release are based on certain assumptions made by Gran Tierra based on management’s experience and other factors believed to be appropriate. Gran Tierra believes these assumptions to be reasonable at this time, but the forward-looking statements are subject to risks and uncertainties, many of which are beyond Gran Tierra’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. All forward-looking statements are made as of the date of this press release and the fact that this press release remains available does not constitute a representation by Gran Tierra that Gran Tierra believes these forward-looking statements continue to be true as of any subsequent date. Actual results may vary materially from the expected results expressed in forward-looking statements. Gran Tierra disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Important Information Regarding the Sale

This press release is neither a solicitation of a proxy nor an offer to purchase nor a solicitation of an offer to sell any securities. This press release is also not a substitute for any proxy statement or other filings that may be made with the SEC with respect to the Sale. Approval of the Sale will be submitted to the Company’s stockholders for their consideration. The Company has filed a preliminary proxy statement with the SEC and will file a definitive proxy statement to be used to solicit stockholder approval of the transaction. Detailed information about the Sale is contained in the preliminary proxy statement and will be contained in the definitive proxy statement and other documents to be filed with the SEC and disseminated to stockholders prior to the meeting.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.